{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:03:21Z","timestamp":1770743001839,"version":"3.49.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100014387","name":"ACADIA Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40263-024-01084-1","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T10:02:05Z","timestamp":1712570525000},"page":"333-347","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["On the Optimal Diagnosis and the Evolving Role of Pimavanserin in Parkinson\u2019s Disease Psychosis"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4052-156X","authenticated-orcid":false,"given":"Fernando L.","family":"Pagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-002X","authenticated-orcid":false,"given":"Paul E.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9676-3832","authenticated-orcid":false,"given":"Yasar","family":"Torres-Yaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9540-6913","authenticated-orcid":false,"given":"Gregory M.","family":"Pontone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"1084_CR1","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson\u2019s disease. Mov Disord. 2015;30:1591\u2013601. https:\/\/doi.org\/10.1002\/mds.26424.","journal-title":"Mov Disord"},{"key":"1084_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson\u2019s disease: variation by age, gender, and race\/ethnicity. Am J Epidemiol. 2003;157:1015\u201322. https:\/\/doi.org\/10.1093\/aje\/kwg068.","journal-title":"Am J Epidemiol"},{"key":"1084_CR3","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e300","author":"JW Han","year":"2018","unstructured":"Han JW, Ahn YD, Kim W-S, et al. Psychiatric manifestation in Patients with Parkinson\u2019s disease. J Korean Med Sci. 2018. https:\/\/doi.org\/10.3346\/jkms.2018.33.e300.","journal-title":"J Korean Med Sci"},{"key":"1084_CR4","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3233\/jpd-213035","volume":"12","author":"CD Stang","year":"2022","unstructured":"Stang CD, Mullan AF, Camerucci E, et al. Incidence, prevalence, and mortality of psychosis associated with Parkinson\u2019s disease (1991\u20132010). J Parkinsons Dis. 2022;12:1319\u201327. https:\/\/doi.org\/10.3233\/jpd-213035.","journal-title":"J Parkinsons Dis"},{"key":"1084_CR5","doi-asserted-by":"publisher","unstructured":"Lenka A, Pagonabarraga J, Pal PK, et al. Minor hallucinations in Parkinson disease. A subtle symptom with major clinical implications. 2019;93, 259-266. https:\/\/doi.org\/10.1212\/wnl.0000000000007913.","DOI":"10.1212\/wnl.0000000000007913"},{"key":"1084_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jns.2009.08.014","volume":"289","author":"G F\u00e9nelon","year":"2010","unstructured":"F\u00e9nelon G, Alves G. Epidemiology of psychosis in Parkinson\u2019s disease. J Neurol Sci. 2010;289:12\u20137. https:\/\/doi.org\/10.1016\/j.jns.2009.08.014.","journal-title":"J Neurol Sci"},{"key":"1084_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2015.00263","author":"RA Wood","year":"2015","unstructured":"Wood RA, Hopkins SA, Moodley KK, et al. Fifty percent prevalence of extracampine hallucinations in Parkinson\u2019s disease patients. Front Neurol. 2015. https:\/\/doi.org\/10.3389\/fneur.2015.00263.","journal-title":"Front Neurol"},{"key":"1084_CR8","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00415-020-09954-6","volume":"267","author":"A Merola","year":"2020","unstructured":"Merola A, Romagnolo A, Dwivedi AK, et al. Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. J Neurol. 2020;267:2949\u201360. https:\/\/doi.org\/10.1007\/s00415-020-09954-6.","journal-title":"J Neurol"},{"key":"1084_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1136\/jnnp.2008.166959","volume":"80","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Br\u00f8nnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2009;80:928\u201330. https:\/\/doi.org\/10.1136\/jnnp.2008.166959.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/wnl.0000000000000801","volume":"83","author":"P de la Riva","year":"2014","unstructured":"de la Riva P, Smith K, Xie SX, et al. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology. 2014;83:1096\u2013103. https:\/\/doi.org\/10.1212\/wnl.0000000000000801.","journal-title":"Neurology"},{"key":"1084_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.26432","volume":"31","author":"J Pagonabarraga","year":"2016","unstructured":"Pagonabarraga J, Martinez-Horta S, Fern\u00e1ndez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson\u2019s disease patients, even from the premotor phase. Mov Disord. 2016;31:45\u201352. https:\/\/doi.org\/10.1002\/mds.26432.","journal-title":"Mov Disord"},{"key":"1084_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/mds.26170","volume":"30","author":"D Weintraub","year":"2015","unstructured":"Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson\u2019s disease. Mov Disord. 2015;30:919\u201327. https:\/\/doi.org\/10.1002\/mds.26170.","journal-title":"Mov Disord"},{"key":"1084_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/brain\/123.4.733","volume":"123","author":"G F\u00e9nelon","year":"2000","unstructured":"F\u00e9nelon G, Mahieux F, Huon R, et al. Hallucinations in Parkinson\u2019s disease: prevalence, phenomenology and risk factors. Brain. 2000;123:733\u201345. https:\/\/doi.org\/10.1093\/brain\/123.4.733.","journal-title":"Brain"},{"key":"1084_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/1531-8257(199901)14:1<117::AID-MDS1019>3.0.CO;2-0","volume":"14","author":"EJ Pappert","year":"1999","unstructured":"Pappert EJ, Goetz CG, Niederman FG, et al. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson\u2019s disease. Mov Disord. 1999;14:117\u201321. https:\/\/doi.org\/10.1002\/1531-8257(199901)14:1%3c117::AID-MDS1019%3e3.0.CO;2-0.","journal-title":"Mov Disord"},{"key":"1084_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrneurol.2016.200","volume":"13","author":"DH ffytche","year":"2017","unstructured":"ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13:81\u201395. https:\/\/doi.org\/10.1038\/nrneurol.2016.200.","journal-title":"Nat Rev Neurol"},{"key":"1084_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jns.2016.03.005","volume":"364","author":"A Lenka","year":"2016","unstructured":"Lenka A, Arumugham SS, Christopher R, et al. Genetic substrates of psychosis in patients with Parkinson\u2019s disease: a critical review. J Neurol Sci. 2016;364:33\u201341. https:\/\/doi.org\/10.1016\/j.jns.2016.03.005.","journal-title":"J Neurol Sci"},{"key":"1084_CR17","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3233\/JPD-212716","volume":"11","author":"B Radojevi\u0107","year":"2021","unstructured":"Radojevi\u0107 B, Draga\u0161evi\u0107-Mi\u0161kovi\u0107 NT, Marjanovi\u0107 A, et al. Clinical and genetic analysis of psychosis in Parkinson\u2019s disease. J Parkinsons Dis. 2021;11:1973\u201380. https:\/\/doi.org\/10.3233\/JPD-212716.","journal-title":"J Parkinsons Dis"},{"key":"1084_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/j.1532-5415.2000.tb06891.x","volume":"48","author":"D Aarsland","year":"2000","unstructured":"Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson\u2019s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48:938\u201342. https:\/\/doi.org\/10.1111\/j.1532-5415.2000.tb06891.x.","journal-title":"J Am Geriatr Soc"},{"key":"1084_CR19","doi-asserted-by":"publisher","unstructured":"Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. What predicts mortality in Parkinson disease? A prospective population-based long-term study. 2010;75, 1270\u20131276. https:\/\/doi.org\/10.1212\/WNL.0b013e3181f61311.","DOI":"10.1212\/WNL.0b013e3181f61311"},{"key":"1084_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1177\/08919887211018280","volume":"34","author":"GS Segal","year":"2021","unstructured":"Segal GS, Xie SJ, S-u-R P, et al. Psychosis in Parkinson\u2019s disease: current treatment options and impact on patients and caregivers. J Geriatr Psychiatry Neurol. 2021;34:274\u20139. https:\/\/doi.org\/10.1177\/08919887211018280.","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"1084_CR21","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/mds.21382","volume":"22","author":"B Ravina","year":"2007","unstructured":"Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson\u2019s disease: Report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061\u20138. https:\/\/doi.org\/10.1002\/mds.21382.","journal-title":"Mov Disord"},{"key":"1084_CR22","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.25270\/altc.2020.8.00001","volume":"28","author":"DP Schneider","year":"2020","unstructured":"Schneider DP, Stefanacci RG, Beier MT, et al. Psychosis in Parkinson disease: overview and management. Ann Longterm Care. 2020;28:e6\u201318. https:\/\/doi.org\/10.25270\/altc.2020.8.00001.","journal-title":"Ann Longterm Care"},{"key":"1084_CR23","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"1084_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.parkreldis.2018.04.008","volume":"54","author":"CV Kulick","year":"2018","unstructured":"Kulick CV, Montgomery KM, Nirenberg MJ. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2018;54:40\u20135. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.04.008.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR25","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40265-016-0600-5","volume":"76","author":"A Chang","year":"2016","unstructured":"Chang A, Fox SH. Psychosis in Parkinson\u2019s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76:1093\u2013118. https:\/\/doi.org\/10.1007\/s40265-016-0600-5.","journal-title":"Drugs"},{"key":"1084_CR26","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1136\/jnnp.2010.234799","volume":"82","author":"G F\u00e9nelon","year":"2011","unstructured":"F\u00e9nelon G, Soulas T, de Langavant LC, et al. Feeling of presence in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2011;82:1219\u201324. https:\/\/doi.org\/10.1136\/jnnp.2010.234799.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1212\/wnl.50.2.515","volume":"50","author":"CG Goetz","year":"1998","unstructured":"Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson\u2019s disease patients. High-dose Challenge Does Not Precipitate Hallucinations. 1998;50:515\u20137. https:\/\/doi.org\/10.1212\/wnl.50.2.515.","journal-title":"High-dose Challenge Does Not Precipitate Hallucinations"},{"key":"1084_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1471-2377-9-23","volume":"9","author":"D Ecker","year":"2009","unstructured":"Ecker D, Unrath A, Kassubek J, et al. Dopamine Agonists and their risk to induce psychotic episodes in Parkinson\u2019s disease: a case-control study. BMC Neurol. 2009;9:23. https:\/\/doi.org\/10.1186\/1471-2377-9-23.","journal-title":"BMC Neurol"},{"key":"1084_CR29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.parkreldis.2008.07.004","volume":"15","author":"WL Baker","year":"2009","unstructured":"Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson\u2019s disease: A meta-analysis. Parkinsonism Relat Disord. 2009;15:287\u201394. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.07.004.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jnnp-2012-304440","volume":"84","author":"RP Munhoz","year":"2013","unstructured":"Munhoz RP, Teive HA, Eleftherohorinou H, et al. Demographic and motor features associated with the occurrence of neuropsychiatric and sleep complications of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 2013;84:883\u20137. https:\/\/doi.org\/10.1136\/jnnp-2012-304440.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR31","first-page":"266","volume":"27","author":"KJ Black","year":"2017","unstructured":"Black KJ. Treatment of Parkinson\u2019s disease psychosis. Med Int Rev. 2017;27:266\u201371.","journal-title":"Med Int Rev"},{"key":"1084_CR32","doi-asserted-by":"publisher","unstructured":"Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. A Report of the AAN Guideline Subcommittee. 2021; 97, 942\u2013957. \/https:\/\/doi.org\/10.1212\/wnl.0000000000012868.","DOI":"10.1212\/wnl.0000000000012868"},{"key":"1084_CR33","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/mds.27602","volume":"34","author":"K Seppi","year":"2019","unstructured":"Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson\u2019s disease\u2014an evidence-based medicine review. Mov Disord. 2019;34:180\u201398. https:\/\/doi.org\/10.1002\/mds.27602.","journal-title":"Mov Disord"},{"key":"1084_CR34","doi-asserted-by":"publisher","first-page":"3256542","DOI":"10.1155\/2017\/3256542","volume":"2017","author":"RN Taddei","year":"2017","unstructured":"Taddei RN, Cankaya S, Dhaliwal S, et al. Management of psychosis in Parkinson\u2019s disease: emphasizing clinical subtypes and pathophysiological mechanisms of the condition. Parkinson\u2019s Disease. 2017;2017:3256542. https:\/\/doi.org\/10.1155\/2017\/3256542.","journal-title":"Parkinson's Disease"},{"key":"1084_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s1474-4422(19)30153-x","volume":"19","author":"JP Taylor","year":"2020","unstructured":"Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19:157\u201369. https:\/\/doi.org\/10.1016\/s1474-4422(19)30153-x.","journal-title":"Lancet Neurol"},{"key":"1084_CR36","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jamaneurol.2023.1835","volume":"80","author":"E d\u2019Angremont","year":"2023","unstructured":"d\u2019Angremont E, Begemann MJH, van Laar T, et al. Cholinesterase inhibitors for treatment of psychotic symptoms in Alzheimer disease and Parkinson disease: a meta-analysis. JAMA Neurol. 2023;80:813\u201323. https:\/\/doi.org\/10.1001\/jamaneurol.2023.1835.","journal-title":"JAMA Neurol"},{"key":"1084_CR37","first-page":"238","volume":"251","author":"HY Meltzer","year":"1989","unstructured":"Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther. 1989;251:238\u201346.","journal-title":"J Pharmacol Exp Ther"},{"key":"1084_CR38","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jamaneurol.2016.0031","volume":"73","author":"D Weintraub","year":"2016","unstructured":"Weintraub D, Chiang C, Kim HM, et al. Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol. 2016;73:535\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2016.0031.","journal-title":"JAMA Neurol"},{"key":"1084_CR39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1176\/appi.ajp.161.1.160","volume":"161","author":"S Janno","year":"2004","unstructured":"Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry. 2004;161:160\u20133. https:\/\/doi.org\/10.1176\/appi.ajp.161.1.160.","journal-title":"Am J Psychiatry"},{"key":"1084_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3988\/jcn.2012.8.1.15","volume":"8","author":"HW Shin","year":"2012","unstructured":"Shin HW, Chung SJ. Drug-induced parkinsonism. J Clin Neurol. 2012;8:15\u201321. https:\/\/doi.org\/10.3988\/jcn.2012.8.1.15.","journal-title":"J Clin Neurol"},{"key":"1084_CR41","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67:674\u201394. https:\/\/doi.org\/10.1111\/jgs.15767.","journal-title":"J Am Geriatr Soc"},{"key":"1084_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1176\/jnp.12.3.364","volume":"12","author":"T Ellis","year":"2000","unstructured":"Ellis T, Cudkowicz ME, Sexton PM, et al. Clozapine and risperidone treatment of psychosis in Parkinson\u2019s disease. J Neuropsychiatry Clin Neurosci. 2000;12:364\u20139. https:\/\/doi.org\/10.1176\/jnp.12.3.364.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1084_CR43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/mds.1258","volume":"17","author":"SA Factor","year":"2002","unstructured":"Factor SA, Molho ES, Friedman JH. Risperidone and parkinson\u2019s disease. Mov Disord. 2002;17:221\u20132. https:\/\/doi.org\/10.1002\/mds.1258.","journal-title":"Mov Disord"},{"key":"1084_CR44","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","volume":"15","author":"E Mohr","year":"2000","unstructured":"Mohr E, Mendis T, Hildebrand K, et al. Risperidone in the treatment of dopamine-induced psychosis in Parkinson\u2019s disease: an open pilot trial. Mov Disord. 2000;15:1230\u20137. https:\/\/doi.org\/10.1002\/1531-8257(200011)15:6%3c1230::AID-MDS1026%3e3.0.CO;2-9.","journal-title":"Mov Disord"},{"key":"1084_CR45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","volume":"52","author":"A Breier","year":"2002","unstructured":"Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson\u2019s disease. Biol Psychiat. 2002;52:438\u201345. https:\/\/doi.org\/10.1016\/S0006-3223(02)01392-6.","journal-title":"Biol Psychiat"},{"key":"1084_CR46","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1002\/mds.10217","volume":"17","author":"WG Ondo","year":"2002","unstructured":"Ondo WG, Levy JK, Vuong KD, et al. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031\u20135. https:\/\/doi.org\/10.1002\/mds.10217.","journal-title":"Mov Disord"},{"key":"1084_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/WNF.0b013e31824d5115","volume":"35","author":"L Pintor","year":"2012","unstructured":"Pintor L, Valldeoriola F, Baill\u00e9s E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in parkinson disease: a randomized open clinical trial. Clin Neuropharmacol. 2012;35:61\u20136. https:\/\/doi.org\/10.1097\/WNF.0b013e31824d5115.","journal-title":"Clin Neuropharmacol"},{"key":"1084_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","volume":"109","author":"J Schindeh\u00fctte","year":"2007","unstructured":"Schindeh\u00fctte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson\u2019s disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg. 2007;109:188\u201391. https:\/\/doi.org\/10.1016\/j.clineuro.2006.07.003.","journal-title":"Clin Neurol Neurosurg"},{"key":"1084_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2069240","author":"SH Isaacson","year":"2022","unstructured":"Isaacson SH, Citrome L. Hallucinations and delusions associated with Parkinson\u2019s disease psychosis: safety of current treatments and future directions. Expert Opin Drug Saf. 2022. https:\/\/doi.org\/10.1080\/14740338.2022.2069240.","journal-title":"Expert Opin Drug Saf"},{"key":"1084_CR50","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1056\/nejm199903113401003","volume":"340","author":"Parkinson Study Group","year":"1999","unstructured":"Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2019s disease. N Engl J Med. 1999;340:757\u201363. https:\/\/doi.org\/10.1056\/nejm199903113401003.","journal-title":"N Engl J Med"},{"key":"1084_CR51","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","volume":"75","author":"P Pollak","year":"2004","unstructured":"Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson\u2019s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689\u201395. https:\/\/doi.org\/10.1136\/jnnp.2003.029868.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR52","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","volume":"99","author":"A Mijovic","year":"2020","unstructured":"Mijovic A, MacCabe JH. Clozapine-induced agranulocytosis. Ann Hematol. 2020;99:2477\u201382. https:\/\/doi.org\/10.1007\/s00277-020-04215-y.","journal-title":"Ann Hematol"},{"key":"1084_CR53","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ph14030238","volume":"14","author":"M Carli","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, et al. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals. 2021;14:238. https:\/\/doi.org\/10.3390\/ph14030238.","journal-title":"Pharmaceuticals"},{"key":"1084_CR54","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2045125316641019","volume":"6","author":"S Maher","year":"2016","unstructured":"Maher S, Cunningham A, O\u2019Callaghan N, et al. Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol. 2016;6:178\u201384. https:\/\/doi.org\/10.1177\/2045125316641019.","journal-title":"Ther Adv Psychopharmacol"},{"key":"1084_CR55","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00213-022-06294-3","volume":"240","author":"D Sanagustin","year":"2023","unstructured":"Sanagustin D, Martin-Subero M, Hogg B, et al. Prevalence of clozapine-induced sialorrhea and its effect on quality of life. Psychopharmacology. 2023;240:203\u201311. https:\/\/doi.org\/10.1007\/s00213-022-06294-3.","journal-title":"Psychopharmacology"},{"key":"1084_CR56","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/mdc3.13582","volume":"9","author":"JH Friedman","year":"2022","unstructured":"Friedman JH. Clozapine Is Severely Underused in Parkinson\u2019s Disease Patients. Mov Disord Clin Pract. 2022;9:1021\u20134. https:\/\/doi.org\/10.1002\/mdc3.13582.","journal-title":"Mov Disord Clin Pract"},{"key":"1084_CR57","unstructured":"Clozaril (clozapine) [prescribing information]. Rosemont (PA): Novartis Pharmaceuticals Corporation; February 2021."},{"key":"1084_CR58","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","volume":"68","author":"R Kurlan","year":"2007","unstructured":"Kurlan R, Cummings J, Raman R, et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology. 2007;68:1356\u201363. https:\/\/doi.org\/10.1212\/01.wnl.0000260060.60870.89.","journal-title":"Neurology"},{"key":"1084_CR59","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/mds.20474","volume":"20","author":"WG Ondo","year":"2005","unstructured":"Ondo WG, Tintner R, Dat Voung K, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord. 2005;20:958\u201363. https:\/\/doi.org\/10.1002\/mds.20474.","journal-title":"Mov Disord"},{"key":"1084_CR60","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.21116","volume":"22","author":"JM Rabey","year":"2007","unstructured":"Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson\u2019s disease patients: a double-blind labeled study of 3 months\u2019 duration. Mov Disord. 2007;22:313\u20138. https:\/\/doi.org\/10.1002\/mds.21116.","journal-title":"Mov Disord"},{"key":"1084_CR61","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/ndt.s5335","volume":"5","author":"P Shotbolt","year":"2009","unstructured":"Shotbolt P, Samuel M, Fox C, et al. A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease. Neuropsychiatr Dis Treat. 2009;5:327\u201332. https:\/\/doi.org\/10.2147\/ndt.s5335.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1084_CR62","unstructured":"Seroquel (quetiapine) [prescribing information]. Wilmington (DE): AstraZeneca Pharmaceuticals LP; February 2022."},{"key":"1084_CR63","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s00702-023-02589-7","volume":"130","author":"C Glocker","year":"2023","unstructured":"Glocker C, Grohmann R, Burkhardt G, et al. Antipsychotic drug-induced neutropenia: results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm (Vienna). 2023;130:153\u201363. https:\/\/doi.org\/10.1007\/s00702-023-02589-7.","journal-title":"J Neural Transm (Vienna)"},{"key":"1084_CR64","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1176\/appi.neuropsych.18080180","volume":"31","author":"JJ Chen","year":"2019","unstructured":"Chen JJ, Hua H, Massihi L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 2019;31:188\u201395. https:\/\/doi.org\/10.1176\/appi.neuropsych.18080180.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1084_CR65","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1124\/jpet.105.097006","volume":"317","author":"KE Vanover","year":"2006","unstructured":"Vanover KE, Weiner DM, Makhay M, et al. Pharmacological and behavioral profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a novel 5-Hydroxytryptamine2A receptor inverse agonist. J Pharmacol Exp Ther. 2006;317:910\u20138. https:\/\/doi.org\/10.1124\/jpet.105.097006.","journal-title":"J Pharmacol Exp Ther"},{"key":"1084_CR66","unstructured":"Nuplazid (pimavanserin) [prescribing information]. San Diego (CA): Acadia Pharmaceuticals Inc; April 2020."},{"key":"1084_CR67","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/npp.2009.176","volume":"35","author":"HY Meltzer","year":"2010","unstructured":"Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson\u2019s disease psychosis. Neuropsychopharmacology. 2010;35:881\u201392. https:\/\/doi.org\/10.1038\/npp.2009.176.","journal-title":"Neuropsychopharmacology"},{"key":"1084_CR68","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1517\/14656566.2013.819345","volume":"14","author":"JH Friedman","year":"2013","unstructured":"Friedman JH. Pimavanserin for the treatment of Parkinson\u2019s disease psychosis. Expert Opin Pharmacother. 2013;14:1969\u201375. https:\/\/doi.org\/10.1517\/14656566.2013.819345.","journal-title":"Expert Opin Pharmacother"},{"key":"1084_CR69","unstructured":"ClinicalTrials.gov. A study of safety and efficacy of pimavanserin (ACP-103) in patients with Parkinson\u2019s disease psychosis. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00658567 Accessed 28 Jan 2023."},{"key":"1084_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","volume":"383","author":"J Cummings","year":"2014","unstructured":"Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial. The Lancet. 2014;383:533\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(13)62106-6.","journal-title":"The Lancet"},{"key":"1084_CR71","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2020.06.026","volume":"77","author":"CG Ballard","year":"2020","unstructured":"Ballard CG, Kreitzman DL, Isaacson S, et al. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson\u2019s disease psychosis. Parkinsonism Relat Disord. 2020;77:100\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.06.026.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR72","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.parkreldis.2021.04.012","volume":"87","author":"SH Isaacson","year":"2021","unstructured":"Isaacson SH, Ballard CG, Kreitzman DL, et al. Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson\u2019s disease psychosis patients. Parkinsonism Relat Disord. 2021;87:25\u201331. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.04.012.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR73","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.parkreldis.2022.08.013","volume":"103","author":"TP Pham Nguyen","year":"2022","unstructured":"Pham Nguyen TP, Thibault D, Hamedani AG, et al. Atypical antipsychotic use and mortality risk in Parkinson disease. Parkinsonism Relat Disord. 2022;103:17\u201322. https:\/\/doi.org\/10.1016\/j.parkreldis.2022.08.013.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR74","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1176\/appi.ajp.21090876","volume":"179","author":"AD Mosholder","year":"2022","unstructured":"Mosholder AD, Ma Y, Akhtar S, et al. Mortality among Parkinson\u2019s disease patients treated with pimavanserin or atypical antipsychotics: an observational study in medicare beneficiaries. Am J Psychiatry. 2022;179:553\u201361. https:\/\/doi.org\/10.1176\/appi.ajp.21090876.","journal-title":"Am J Psychiatry"},{"key":"1084_CR75","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s40264-022-01260-6","volume":"46","author":"JB Layton","year":"2023","unstructured":"Layton JB, Forns J, McQuay LJ, et al. Mortality in patients with Parkinson\u2019s disease-related psychosis treated with pimavanserin compared with other atypical antipsychotics: a cohort study. Drug Saf. 2023;46:195\u2013208. https:\/\/doi.org\/10.1007\/s40264-022-01260-6.","journal-title":"Drug Saf"},{"key":"1084_CR76","unstructured":"US Food and Drug Administration. FDA analysis finds no new or unexpected safety risks associated with Nuplazid (pimavanserin), a medication to treat the hallucinations and delusions of Parkinson\u2019s disease psychosis. 2018. Available at: https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm621160.htm. Accessed 9 Jun 2022."},{"key":"1084_CR77","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(18)31002-X","volume":"391","author":"P Webster","year":"2018","unstructured":"Webster P. Pimavanserin evaluated by the FDA. The Lancet. 2018;391:1762. https:\/\/doi.org\/10.1016\/S0140-6736(18)31002-X.","journal-title":"The Lancet"},{"key":"1084_CR78","doi-asserted-by":"publisher","DOI":"10.1177\/08919887231154933","author":"I Yunusa","year":"2023","unstructured":"Yunusa I, Rashid N, Seyedin R, et al. Comparative efficacy, safety, and acceptability of pimavanserin and other atypical antipsychotics for Parkinson\u2019s disease psychosis: systematic review and network meta-analysis. J Geriatr Psychiatry Neurol. 2023;36(5):417\u201332. https:\/\/doi.org\/10.1177\/08919887231154933.","journal-title":"J Geriatric Psychiatry Neurol"},{"key":"1084_CR79","unstructured":"Pimavanserin vs. Quetiapine for the Treatment Parkinson\u2019s Psychosis (C-SAPP). ClinicalTrials.gov identifier NCT04373317. Updated 3 May 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04373317. Accessed 7 May 2022."},{"key":"1084_CR80","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1176\/appi.ajp.162.10.1785","volume":"162","author":"DO Perkins","year":"2005","unstructured":"Perkins DO, Gu H, Boteva K, et al. Relationship Between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162:1785\u2013804. https:\/\/doi.org\/10.1176\/appi.ajp.162.10.1785.","journal-title":"Am J Psychiatry"},{"key":"1084_CR81","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.schres.2005.05.024","volume":"79","author":"MG Harris","year":"2005","unstructured":"Harris MG, Henry LP, Harrigan SM, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr Res. 2005;79:85\u201393. https:\/\/doi.org\/10.1016\/j.schres.2005.05.024.","journal-title":"Schizophr Res"},{"key":"1084_CR82","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, et al. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62:975\u201383. https:\/\/doi.org\/10.1001\/archpsyc.62.9.975.","journal-title":"Arch Gen Psychiatry"},{"key":"1084_CR83","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/j.1600-0404.1991.tb04918.x","volume":"84","author":"A Friedman","year":"1991","unstructured":"Friedman A, Sienkiewicz J. Psychotic complications of long-term levodopa treatment of Parkinson\u2019s disease. Acta Neurol Scand. 1991;84:111\u20133. https:\/\/doi.org\/10.1111\/j.1600-0404.1991.tb04918.x.","journal-title":"Acta Neurol Scand"},{"key":"1084_CR84","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/01.Wnl.0000103444.45882.D8","volume":"62","author":"V Biousse","year":"2004","unstructured":"Biousse V, Skibell BC, Watts RL, et al. Ophthalmologic features of Parkinson\u2019s disease. Neurology. 2004;62:177\u201380. https:\/\/doi.org\/10.1212\/01.Wnl.0000103444.45882.D8.","journal-title":"Neurology"},{"key":"1084_CR85","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.parkreldis.2008.11.013","volume":"15","author":"CL Dotchin","year":"2009","unstructured":"Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson\u2019s disease in Tanzania. Parkinsonism Relat Disord. 2009;15:457\u201360. https:\/\/doi.org\/10.1016\/j.parkreldis.2008.11.013.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/mds.10567","volume":"18","author":"W Poewe","year":"2003","unstructured":"Poewe W. Psychosis in Parkinson\u2019s disease. Mov Disord. 2003;18:80\u20137. https:\/\/doi.org\/10.1002\/mds.10567.","journal-title":"Mov Disord"},{"key":"1084_CR87","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1136\/jnnp.2008.153163","volume":"79","author":"TR Thomsen","year":"2008","unstructured":"Thomsen TR, Panisset M, Suchowersky O, et al. Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry. 2008;79:1413\u20135. https:\/\/doi.org\/10.1136\/jnnp.2008.153163.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105356","volume":"109","author":"BH Thames","year":"2023","unstructured":"Thames BH, Ondo WG. Clozapine: efficacy for Parkinson disease psychosis in patients refractory to pimavanserin. Parkinsonism Relat Disord. 2023;109: 105356. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105356.","journal-title":"Parkinsonism Relat Disord"},{"key":"1084_CR89","doi-asserted-by":"publisher","first-page":"2603641","DOI":"10.1155\/2021\/2603641","volume":"2021","author":"K Dashtipour","year":"2021","unstructured":"Dashtipour K, Gupta F, Hauser RA, et al. Pimavanserin treatment for Parkinson\u2019s disease psychosis in clinical practice. Parkinson\u2019s Disease. 2021;2021:2603641. https:\/\/doi.org\/10.1155\/2021\/2603641.","journal-title":"Parkinson's Disease"},{"key":"1084_CR90","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.schres.2019.02.018","volume":"208","author":"HA Nasrallah","year":"2019","unstructured":"Nasrallah HA, Fedora R, Morton R. Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist. Schizophr Res. 2019;208:217\u201320. https:\/\/doi.org\/10.1016\/j.schres.2019.02.018.","journal-title":"Schizophr Res"},{"key":"1084_CR91","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1017\/s1461145705005250","volume":"8","author":"E Lindstr\u00f6m","year":"2005","unstructured":"Lindstr\u00f6m E, Farde L, Eberhard J, et al. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. Int J Neuropsychopharmacol. 2005;8:615\u201329. https:\/\/doi.org\/10.1017\/s1461145705005250.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1084_CR92","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/pds.1607","volume":"17","author":"C \u00c5str\u00f6m-Lilja","year":"2008","unstructured":"\u00c5str\u00f6m-Lilja C, Odeberg JM, Ekman E, et al. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17:587\u201392. https:\/\/doi.org\/10.1002\/pds.1607.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1084_CR93","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.622","volume":"8","author":"Y Huang","year":"2020","unstructured":"Huang Y, Alsabbagh MW. Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias\u2014a narrative review. Pharmacol Res Perspect. 2020;8: e00622. https:\/\/doi.org\/10.1002\/prp2.622.","journal-title":"Pharmacol Res Perspect"},{"key":"1084_CR94","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1253\/circrep.CR-20-0115","volume":"3","author":"S Kuwahata","year":"2021","unstructured":"Kuwahata S, Takenaka T, Motoya T, et al. Effect of QT prolongation in patients taking cholinesterase inhibitors (Donepezil) for Alzheimer\u2019s disease. Circ Rep. 2021;3:115\u201321. https:\/\/doi.org\/10.1253\/circrep.CR-20-0115.","journal-title":"Circ Rep"},{"key":"1084_CR95","doi-asserted-by":"publisher","first-page":"204209862094241","DOI":"10.1177\/2042098620942416","volume":"11","author":"K Malone","year":"2020","unstructured":"Malone K, Hancox JC. QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine. Ther Adv Drug Saf. 2020;11:2042098620942416. https:\/\/doi.org\/10.1177\/2042098620942416.","journal-title":"Ther Adv Drug Saf"},{"key":"1084_CR96","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12028-008-9125-4","volume":"10","author":"EJ Newman","year":"2009","unstructured":"Newman EJ, Grosset DG, Kennedy PGE. The Parkinsonism-hyperpyrexia syndrome. Neurocrit Care. 2009;10:136\u201340. https:\/\/doi.org\/10.1007\/s12028-008-9125-4.","journal-title":"Neurocrit Care"},{"key":"1084_CR97","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1136\/jnnp.65.5.774","volume":"65","author":"JM Graham","year":"1998","unstructured":"Graham JM, Sussman JD, Ford KS, et al. Olanzapine in the treatment of hallucinosis in idiopathic parkinson\u2019s disease: a cautionary note. J Neurol Neurosurg Psychiatry. 1998;65:774\u20137. https:\/\/doi.org\/10.1136\/jnnp.65.5.774.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1084_CR98","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1212\/wnl.47.4.1085","volume":"47","author":"EC Wolters","year":"1996","unstructured":"Wolters EC, Jansen ENH, Tuynman-Qua HG, et al. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson\u2019s disease. Neurology. 1996;47:1085\u20137. https:\/\/doi.org\/10.1212\/wnl.47.4.1085.","journal-title":"Neurology"},{"key":"1084_CR99","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JPD-181448","volume":"9","author":"JR Younce","year":"2019","unstructured":"Younce JR, Davis AA, Black KJ. A Systematic review and case series of ziprasidone for psychosis in Parkinson\u2019s disease. J Parkinsons Dis. 2019;9:63\u201371. https:\/\/doi.org\/10.3233\/JPD-181448.","journal-title":"J Parkinsons Dis"},{"key":"1084_CR100","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136891.17006.ec","author":"L Morgante","year":"2004","unstructured":"Morgante L, Epifanio A, Spina E, et al. Quetiapine and clozapine in Parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol. 2004. https:\/\/doi.org\/10.1097\/01.wnf.0000136891.17006.ec.","journal-title":"Clin Neuropharmacol"},{"key":"1084_CR101","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/01.Wnf.0000236769.31279.19","volume":"29","author":"D Merims","year":"2006","unstructured":"Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson\u2019s disease psychosis. Clin Neuropharmacol. 2006;29:331\u20137. https:\/\/doi.org\/10.1097\/01.Wnf.0000236769.31279.19.","journal-title":"Clin Neuropharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01084-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01084-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01084-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T16:14:46Z","timestamp":1713456886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01084-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1084"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01084-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"11 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript was based on a consensus meeting discussion funded by Acadia, which all authors attended. Medical writing assistance, funded by Acadia, was provided by Bryan Marques (Fingerpaint Medical Communications).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Fernando L. Pagan is a speaker\/consultant for Acorda, Acadia, Adamas, Amneal, Kyowa Kirin, Neurocrine, Supernus, Teva, and US WorldMeds. He has received educational and research grants from Novartis, US WorldMeds and Medtronic, as well as NIH\/NIA and Sun Pharma funding for clinical trials. He is the cofounder and Board member of KeifeRx. Paul E. Schulz is funded by the McCord Family Professorship in Neurology, the Umphrey Family Professorship in Neurodegenerative Disorders, multiple NIH grants, and several foundations. He has served as a consultant and speaker for Eli Lilly, Biogen, and Acadia Pharmaceuticals, and has contracts with multiple pharmaceutical companies to perform clinical trials. Yasar Torres-Yaghi is a speaker and consultant for AbbVie, Acorda, Acadia, Amneal, Sunovion, Teva, Kyowa Kirin, and Abbott. Gregory M. Pontone is currently funded by NIH grants and in the past has received funding from foundations and participated in industry-sponsored clinical trials. He has consulted for Acadia Pharmaceuticals and GE Healthcare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the writing of this manuscript (initial meeting, outline development, first draft, subsequent revisions) along with medical writing assistance provided by Bryan Marques (Fingerpaint Medical Communications). All authors have read and approved the final submitted manuscript and agree to be accountable for this work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}